Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
The primary purpose of the study is to determine, whether the addition of 5-azacytidine to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).
Acute Myeloid Leukemia
DRUG: azacitidine|DRUG: standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine
Median Event Free Survival (EFS) of all AML patients, continously up to 12 months after start of study
Median event free survival of AML patients with different cytogenetic and molecular risk groups, continously up to 12 months after study start|Median overall survival of all AML patients, continously up to 12 month after start of study|Median overall survival of AML patients with different cytogenetic and molecular risk groups, continously up to 12 month after start of study|Relapse free survival, continously up to 12 months after start of study
The primary purpose of the study is to determine, whether the addition of 5-azacytidine to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).